Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients
HydrustomaC3 - Randomized Clinical Trial to Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients
The surgical ostomy process happens when it is necessary to open an organ (such as the intestine) in order to maintain a communication channel with the external environment. The need for ostomy surgery can happen as a result of illness, genetic factors, or trauma. Despite the extensive improvements in colorectal surgery, in case there is a need for total or partial extraction and exteriorization of the large intestine (colostomy), it is often necessary to perform a stoma that connects the end of the preserved intestine to the skin, in which cases it is necessary to place a a colostomy bag for stool collection. Thus, there is a substantial number of patients who need to live with a permanent abdominal stoma that significantly affects their quality of life, implying significant changes, both physical and social. It will then be necessary for patients to adjust their daily routines in order to deal with stoma care.
The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Braga, Portugal, 4710
- Hospital de Braga
-
Penafiel, Portugal, 4560
- Centro Hospitalar do Tâmega e Sousa
-
Santa Maria Da Feira, Portugal, 4520
- Centro Hospitalar de Entre o Douro e Vouga
-
Vila Nova De Gaia, Portugal, 4430
- Centro Hospitalar de Vila Nova de Gaia/Espinho
-
Vila Real, Portugal, 5000
- Centro Hospitalar de Tras-os-Montes e Alto Douro
-
-
Braga
-
Guimarães, Braga, Portugal, 4835
- Hospital da Senhora da Oliveira - Guimarães
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent;
- Male and Female patients;
- Adult aged ≥ 18;
- Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study;
- Having formed stool and using a flat ostomy appliance;
- Able to understand the study procedures and fill questionaries;
- Able to apply and remove the ostomy device autonomously.
Exclusion Criteria:
- Repeated experiences of leakage with the usual ostomy device,
- Chronically liquid stools,
- Peristomal skin disorders,
- Known allergic reactions to components of the device,
- Receiving chemotherapy, radiation therapy or steroids in the previous month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hydrustoma C3
The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.
|
The participant will use the device for 14 days.
The participant will use the device for 14 days.
|
|
Other: Coloplast Alterna
The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.
|
The participant will use the device for 14 days.
The participant will use the device for 14 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of the device (journal of capsule/bag changes)
Time Frame: 14 days
|
Efficacy will be accessed by asking patients to record on a journal/diary, for each capsule/bag change, what was the reason for the change, and the occurrence and level of leakage.
|
14 days
|
|
Quality of life of the participant (Stoma Quality of Life questionnaire)
Time Frame: 14 days
|
In order to compare stoma related quality of life in patients with colostomy when using a control device and the Hydrustoma C3 devices the Stoma Quality of Life questionnaire will be used.
This questionnaire is composed of 20 questions.
Example of question "I worry that the bag detaches.".
All questions must be answered on a scale of 1 to 4, being 1 always and 4 never.
|
14 days
|
|
Adverse effects
Time Frame: 14 days
|
Safety evaluations will be done by monitoring adverse events.
|
14 days
|
|
Safety of the device (Discolouration, Erosion, Tissue overgrowth score)
Time Frame: 14 days
|
Safety evaluations will be done by monitoring the peristomal skin using the validated Ostomy Skin tool (DET score).
The DET Score is calculated by examining the peristomal skin and evaluate the skin based on the descriptions in each of the 3 domains, discolouration (D), erosion (E) and tissue overgrowth (T); and assessing the size of the area affected in each of the 3 domains.
The total score is (maximum 15) calculated by adding all of the subscores from each domain together.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Satisfaction of the participant (questionnaire)
Time Frame: 14 days
|
The patients will be asked to evaluate the medical device in terms of application, discretion of the device, stoma related noise, feelings of security (confidence) and overall satisfaction of use (including comfort and impact on body image).
The questionnaire has 8 questions of multiple choice (example "Regarding the safety during usage of the devices, I feel: (1) very insecure; (2) moderately insecure; (3) Moderadately secure; (4) Very secure") and 1 open answer question.
|
14 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Palmira Peixoto, Hospital de Braga
- Principal Investigator: Paula Costa, Hospital da Senhora da Oliveira - Guimarães
- Principal Investigator: Liliana Miranda, Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro
- Principal Investigator: Sara Costa, Centro Hospitalar de Entre o Douro e Vouga
- Principal Investigator: Glória Gonçalves, Centro Hospitalar de Vila Nova de Gaia/Espinho
- Principal Investigator: Carla Nunes, Centro Hospitalar do Tâmega e Sousa
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HydrustomaC3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.